| Literature DB >> 26713046 |
Abstract
This study involved a cost-utility analysis of early diagnosis and treatment of diabetic retinopathy depending on the screening strategy used. The four screening strategies evaluated were no screening, opportunistic examination, systematic fundus photography, and systematic examination by an ophthalmologists. Each strategy was evaluated in 10,000 adults aged 40 yr with newly diagnosed diabetes mellitus (hypothetical cohort). The cost of each strategy was estimated in the perspective of both payer and health care system. The utility was estimated using quality-adjusted life years (QALY). Incremental Cost Effectiveness Ratio (ICER) for the different screening strategies was analyzed. After exclusion of the weakly dominating opportunistic strategy, the ICER of systematic photography was 57,716,867 and that of systematic examination by ophthalmologists was 419,989,046 from the perspective of the healthcare system. According to the results, the systematic strategy is preferable to the opportunistic strategy from the perspective of both a payer and a healthcare system. Although systematic examination by ophthalmologists may have higher utility than systematic photography, it is associated with higher cost. The systematic photography is the best strategy in terms of cost-utility. However systematic examination by ophthalmologists can also be a suitable policy alternative, if the incremental cost is socially acceptable.Entities:
Keywords: Cost-utility Analysis; Diabetic Retinopathy; Markov Model; Quality-Adjusted Life Years (QALY)
Mesh:
Year: 2015 PMID: 26713046 PMCID: PMC4689815 DOI: 10.3346/jkms.2015.30.12.1723
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Fig. 1Markov model of no screening group. A decision node (□) is the decision to test a contact by using the respective screening procedure. Branches from a change node (○) represent the possible outcomes of an event; terminal nodes (◃) are assigned the cost of a prior series of actions and events. Probabilities (p): see model specifications; #: complementary probability (all probabilities of chance node's branches to sum to 1.0). pNR, probability of no retinopathy; pNPDR, probability of NPDR; pPDR, probability of PDR; pCSME, probability of CSME; pNPDRobs, probability of remained NPDR; pNPDRtoPDR, probability of NPDR to PDR; pNPDRtoCSME, probability of NPDR to CSME; pPDRnolaserSVL, probability of PDR to SVL after no laser therapy; pCSMEnolaserSVL, probability of CSME to SVL after no laser therapy.
Fig. 2Markov model of opportunistic examination group. pOeNE, probability of not examined in opportunistic examination group; pPDRlaserSVL, probability of PDR to SVL after laser therapy; pCSMElaserSVL, probability of CSME to SVL after laser therapy; pSpNR, probability of no retinopathy in systematic photography group; pSpNPR, probability of negative predictive ratio in systematic photography group; pSpPPR, probability of positive predictive ratio in systematic photography group.
Fig. 3Markov model of systematic photography group.
Fig. 4Markov model of systematic examination by ophthalmologists.
Medical cost of diabetic retinopathy
| Cost items | Cost (KRW) | ||
|---|---|---|---|
| Screening cost | Fundus photography method | Fundus photography basic (E6670) | 8,329 |
| Refraction test (E6710) | 9,534 | ||
| Fundus examination method | Fundus examination (E6660) | 7,299 | |
| Slit-lamp biomicroscopy (E6810) | 2,114 | ||
| Refraction test (E6710) | 9,534 | ||
| Tonometry (E6752) | 2,101 | ||
| Doctor's consultation for outpatient | 13,743 | ||
| Management of diabetic retinopathy cost | Annual NPDR follow-up | Fundus examination method * 2 | 91,434 |
| Fundus fluorescein angiography * 1/2 | 38,353 | ||
| Annual PDR follow-up | Fundus examination method * 4 | 182,869 | |
| Fundus fluorescein angiography * 1 | 76,707 | ||
| Optical coherence tomography * 1 | 165,000 | ||
| Annual CSME Follow-up | Fundus examination method * 4 | 182,869 | |
| Fundus Fluorescein angiography * 1 | 76,707 | ||
| Optical coherence tomography * 1 | 165,000 | ||
| PDR laser therapy | Fundus examination method * 10 | 457,172 | |
| Fundus photocoagulation * 10 | 906,098 | ||
| CSME laser therapy | Fundus examination method * 4 | 182,869 | |
| Fundus photocoagulation * 4 | 362,439 | ||
KRW, Korean won (average exchange rate in 2013 was 1 USD=1,094.70 KRW); NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; CSME, clinically significant macula edema.
Non-medical cost of diabetic retinopathy
| Cost items | Cost (KRW) | |
|---|---|---|
| Transportation cost | Fundus photography screening method | 2,571 |
| Fundus examination screening method | 5,141 | |
| Out-patient management | 5,141 | |
| Fundus laser therapy | 9,254 | |
| Time cost | Fundus photography screening method | 11,283 |
| Fundus examination screening method | 17,664 | |
| Out-patient management | 17,664 | |
| Fundus laser therapy | 22,557 | |
| Nursing cost of a guardian | Fundus laser therapy | 14,326 |
KRW, Korean won (average exchange rate in 2013 was 1 USD=1,094.70 KRW).
Incremental cost effectiveness ratio of diabetic retinopathy screening methods according to a payer perspective
| Comparators | ΔCost*(KRW) | ΔQALY† | ICER‡ (ΔC/ΔQ) |
|---|---|---|---|
| No screening (base line) | - | - | - |
| Opportunistic examination | 12,744,808,602 | 260.3 | 48,961,339 |
| Systematic photography | 19,001,854,196 | 436.07 | 43,575,592 |
| Systematic examination by ophthalmologists | 2,792,113,902 | 9.06 | 308,193,813 |
| No screening (base line) | - | - | - |
| Opportunistic examination | Weakly dominated | ||
| Systematic photography | 31,746,662,798 | 696.37 | 45,588,788 |
| Systematic examination by ophthalmologists | 2,792,113,902 | 9.06 | 308,193,813 |
Discounting rate 5%. *Incremental cost per 10,000 person; †Incremental quality-adjusted life years per 10,000 person; ‡Incremental cost effectiveness ratio per 10,000 person. KRW, Korean won.
Incremental cost effectiveness ratio of diabetic retinopathy screening methods according to health care system perspective
| Comparators | ΔCost*(KRW) | ΔQALY† | ICER‡ (ΔC/ΔQ) |
|---|---|---|---|
| No screening (baseline) | - | - | - |
| Opportunistic examination | 16,234,976,916 | 260.3 | 62,369,412 |
| Systematic photography | 23,957,316,056 | 436.07 | 54,939,598 |
| Systematic examination by ophthalmologists | 3,804,934,443 | 9.06 | 419,989,046 |
| No screening (baseline) | - | - | - |
| Opportunistic examination | Weakly dominated | ||
| Systematic photography | 40,192,292,972 | 696.37 | 57,716,867 |
| Systematic examination by ophthalmologists | 3,804,934,443 | 9.06 | 419,989,046 |
Discounting rate 5%. *Incremental cost per 10,000 person; †Incremental quality-adjusted life years per 10,000 person; ‡Incremental cost effectiveness ratio per 10,000 person. KRW, Korean won.